文献速递前列腺癌

机器人辅助腹腔镜前列腺癌根治术当日出院:可行性、安全性与患者体验

Same-day discharge robot-assisted laparoscopic prostatectomy: feasibility, safety and patient experience.
PubMed 文献 · BJU Int · 2023-03-16

单中心报告2015年6月至2021年12月180例经筛选连续患者接受机器人辅助腹腔镜前列腺癌根治术并计划当日出院,169例(93.8%)成功当日出院,30天再入院率3%,13例早期并发症中5例为Clavien-Dindo分级≥3级,作者认为联合加速康复外科(ERAS)方案可实现安全当日出院且患者接受度高。

要点

  • 180例中169例(93.8%)成功当日出院,30天再入院率3%。
  • 早期(0-30天)并发症13例,其中Clavien-Dindo分级≥3级5例,原文称若留院首夜这些并发症均无法避免。
  • 121例连续患者中107例(88%)返回满意度问卷,92%偏好在家康复,94%表示已准备好回家。

核心结论

  • 机器人辅助腹腔镜前列腺癌根治术联合ERAS方案可使患者于手术当日安全出院,该选择可行且受患者欢迎,其发病率与肿瘤学结局与非当日出院或23小时住院的RALP相似。

研究设计与样本

  • 单中心研究,2015年6月至2021年12月共180例经预先筛选的连续患者接受RALP并计划当日出院,手术由两名外科医生完成,采用ERAS方案,分析当日出院可行性、并发症率、肿瘤学结局及术后患者体验。

主要发现

  • 180例中169例(93.8%)成功于手术当日出院。
  • 中位(范围)年龄63(44-74)岁,中位(范围)控制台时间97(61-256)分钟,出血量200(20-800)mL。
  • 切除标本病理:pT2 69.4%、pT3a 24.4%、pT3b 6.5%;Gleason分级分组GGG 1为25.9%、GGG 2-3为65.7%、GGG 4-5为8.4%。
  • 手术切缘阳性25例(14.7%),其中pT2病例18例(15.5%)、pT3病例7例(13.4%)。
  • 无早期(<90天)生化复发(定义为前列腺特异性抗原>0.2 ng/mL);30天再入院率3%;早期(0-30天)并发症13例,其中Clavien-Dindo分级≥3级5例,原文称若患者术后首夜留院这些并发症均无法避免。

关键数值与推荐

  • 121例连续患者中107例(88%)返回满意度问卷,92%的应答者表示偏好在家康复,94%表示感觉已准备好回家。

临床怎么用

  • 原文结论认为RALP联合ERAS方案允许患者在手术当日安全出院,是可行且受患者欢迎的选择,其发病率与肿瘤学结局与非当日出院或23小时住院的RALP相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To report a single centre's experience of the feasibility, safety and patient acceptability of same-day discharge robot-assisted laparoscopic prostatectomy (RALP). SUBJECTS/PATIENTS AND METHODS: Between June 2015 and December 2021, a total of 180 pre-selected consecutive patients underwent RALP with the intention to discharge on the same day as surgery. Cases were performed by two surgeons. An enhanced recovery after surgery (ERAS) programme was used. The feasibility of same-day discharge was analysed, along with the complication rate, oncological outcomes, and postoperative patient experience. RESULTS: Of 180 patients, 169 (93.8%) were successfully discharged on the same day as surgery. The median (range) age was 63 ( 44-74) years. The median (range) console time was 97 (61-256) min and blood loss was 200 (20-800) mL. The resection specimen pathology results were: pT2 69.4%, pT3a 24.4% and pT3b 6.5%. With regard to Gleason Grade Group (GGG), 25.9% had GGG 1, 65.7% had GGG 2-3 and 8.4% had GGG 4-5 disease. Positive surgical margins were present in 25 cases (14.7%), 18 (15.5%) of which occurred in pT2 cases, and seven (13.4%) in pT3 cases. There were no early (<90 days) biochemical relapses (defined as prostate-specific antigen level >0.2 ng/mL). The 30-day readmission rate was 3%. A total of 13 early (0-30 days) complications were observed, five of which were Clavien-Dindo grade ≥3, however, none of these would have been avoided had the patient remained in hospital on the first postoperative night. Of 121 consecutive patients, 107 (88%) returned a satisfaction questionnaire, and 92% of responders stated they preferred recovery at home, with 94% stating they felt ready to go home. CONCLUSION: Robot-assisted laparoscopic prostatectomy combined with an ERAS programme allows patients to be safely discharged home on the same day of their surgery. This is a feasible option, well-liked by patients, with morbidity and oncological outcomes similar to non-day-case or 23 h stay RALP.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Hill GT, Jeyanthi M, Coomer W, et al. Same-day discharge robot-assisted laparoscopic prostatectomy: feasibility, safety and patient experience. BJU Int. 2023. PMID: 36866941. doi:10.1111/bju.16002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。